Palomino Laboratories Inc.
PALX· OTC
PALXPalomino Laboratories Inc.
Filed Aug 5, 2026 · 10-Q · 36 days after period end · 0001493152-26-036061
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$1.37M | $389.42K | $346.00 | -$4.25K |
| EPS Diluted | -$0.06 | $0.15 | -$0.01 | -$0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palomino Laboratories Inc. · CIK 1938569 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 5, 2026 · 36 d after period end
